USPTO Examiner DAHLIN HEATHER RAQUEL - Art Unit 1629

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18431262COMBINATION THERAPY FOR TREATING CANCERFebruary 2024May 2025Abandon1501NoNo
18372398METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASESeptember 2023January 2025Abandon1610NoNo
18372495METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASESeptember 2023January 2025Abandon1610NoNo
18185268TREATMENT OF LOW-GRADE GLIOMA WITH MIRDAMETINIBMarch 2023January 2025Abandon2310NoNo
1817707318-MC SALT FORMSMarch 2023January 2025Abandon2301NoNo
18057738Pyrazolo Compounds and Methods of Use ThereofNovember 2022May 2024Allow1810NoNo
18056877Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use ThereofNovember 2022September 2024Abandon2220NoNo
18056717SALT AND SOLID FORMS OF TABERNANTHALOGNovember 2022April 2024Abandon1710NoNo
17983971Treatment of Hypercoagulopathy in Cushing's Syndrome by Administration of Glucocorticoid Receptor ModulatorsNovember 2022May 2024Allow1821NoNo
17970938Phytol-based surfactants and methods thereforOctober 2022June 2024Allow2020NoNo
18045210RADIATION-ACTIVATABLE PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USEOctober 2022June 2024Allow2020NoNo
17934769NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAMSeptember 2022March 2024Abandon1810NoNo
17940984PREPARATION METHOD OF TOFACITINIB CITRATESeptember 2022September 2023Allow1200YesNo
17902795USES OF CORYLIN AND/OR NEOBAVAISOFLAVONE IN TREATING SYMPTOMS ASSOCIATED WITH SENESCENCESeptember 2022December 2024Abandon2740NoNo
17892651COMBINATION THERAPY FOR TREATING CANCERAugust 2022May 2024Abandon2011NoNo
17866008METHODS OF USING SUBSTITUTED FLAVONES FOR TREATING BONE DISORDERSJuly 2022March 2025Abandon3321NoNo
17793275CRYSTAL FORM OF POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITORJuly 2022June 2025Allow3510YesNo
17860599Dermatological Compositions and Methods of Treatment against Cutaneous T-Cell LymphomaJuly 2022July 2024Abandon2420NoNo
17857970PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERTENSIONJuly 2022April 2024Abandon2210NoNo
17855823PREPARATION AND APPLICATION OF TRITERPENOIDS WITH EFFECT OF IMPROVING GLUCOSE AND LIPID METABOLISM DISORDERSJuly 2022March 2024Allow2111YesNo
17854685MULTI-FUNCTIONAL NANOPARTICLE TARGETED TO BREAST CANCER, PREPARATION METHOD AND USE THEREOFJune 2022May 2024Abandon2311NoNo
17838171DUAL TREATMENT OF MIGRAINEJune 2022July 2024Abandon2520NoNo
17775795NOVEL SALT OF TERPHENYL COMPOUNDMay 2022May 2025Allow3610YesNo
17733419METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASEApril 2022May 2024Abandon2511NoNo
17732124PRC1 INHIBITORS AND METHODS OF TREATMENT THEREWITHApril 2022April 2025Allow3621NoNo
17730764METHODS OF TREATING AND PREVENTING GRAFT VERSUS HOST DISEASEApril 2022June 2024Abandon2611NoNo
17703891PREPARATION OF GHRELIN O-ACYLTRANSFERASE INHIBITORSMarch 2022February 2025Allow3500NoNo
17700063COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL DERIVATIVEMarch 2022November 2024Abandon3120NoNo
17627946CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOFJanuary 2022May 2025Allow3910YesNo
17617011METHOD FOR TREATMENT OF AT RISK PATIENTSDecember 2021May 2025Abandon4110NoNo
17596227POLYMORPH OF CDK9 INHIBITOR AND PREPARATION METHOD FOR POLYMORPH AND USE THEREOFDecember 2021March 2025Allow3910NoNo
17542540NOVEL ESTERS OF MEDROXYPROGESTERONEDecember 2021May 2025Abandon4110NoNo
17615369COMPOSITION FOR CASPASE INHIBITOR PRODRUG INJECTIONNovember 2021May 2025Abandon4110NoNo
17610368METHODS AND FORMULATIONS FOR TREATING VISION DISORDERSNovember 2021April 2025Abandon4210NoNo
17606998COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCEROctober 2021February 2025Allow4021YesNo
17510050Treating Y537S Mutant Breast Cancer with RAD1901 and mTOR inhibitorOctober 2021August 2023Allow2220YesNo
17509238SYSTEMS AND METHODS FOR TREATMENTS OF AN EYE WITH A PHOTOSENSITIZEROctober 2021September 2024Allow3521YesNo
17599847PRODUCTION METHOD FOR RARE FATTY ACID USING NOVEL ENZYME, AND NOVEL RARE FATTY ACIDSeptember 2021April 2025Allow4311YesNo
17599338PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOFSeptember 2021March 2024Abandon3001NoNo
17598611SYNTHESIS AND APPLICATION OF DILTIAZEM HYDROCHLORIDESeptember 2021March 2025Abandon4110NoNo
17439630COMPOUNDS FOR USES IN PHARMACOLOGICAL INDUCTION OF HBF FOR TREATMENT OF SICKLE CELL DISEASE AND �-THALASSEMIASeptember 2021December 2024Allow3910NoNo
17438753CRYSTAL FORM E OF BULLEYACONITINE A, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFSeptember 2021February 2025Abandon4110NoNo
174370301-PYRIDYL-PYRAZOLYL AMIDE COMPOUNDS AND PREPARATION AND USES THEREOFSeptember 2021May 2025Abandon4411NoNo
17412851DIETARY SUPPLEMENT FORMULATED BASED ON ALL-TRANS FORM OF MENAQUINONE-7August 2021April 2024Abandon3231NoNo
17425810MEDICAMENT FOR PROPHYLAXIS OR TREATMENT OF PULMONARY FIBROSISJuly 2021January 2025Abandon4210NoNo
17423745CRYSTALLINE FORMS OR AMORPHOUS FORMS OF N-(PHENYL SULFONYL) BENZAMIDE COMPOUNDS OR ITS SALTS OR SOLVATESJuly 2021March 2025Allow4420NoNo
17416711CYCLIN-DEPENDENT KINASE INHIBITORSJune 2021May 2025Abandon4720NoNo
17413327CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALSJune 2021October 2024Abandon4010NoNo
17413185CYCLOBUTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALSJune 2021October 2024Abandon4010NoNo
17295721AN AURORA A KINASE INHIBITOR FOR USE IN THE TREATMENT OF NEUROBLASTOMAMay 2021August 2024Abandon3810NoNo
17292863FORMULATIONS OF INFLUENZA THERAPEUTICSMay 2021July 2024Allow3810NoNo
17313955EPINEPHRINE SPRAY FORMULATIONSMay 2021September 2024Abandon4110NoNo
17291273MONOBACTAM COMPOUNDS AND USE THEREFORMay 2021September 2024Abandon4010NoNo
17289122METHOD OF TREATMENT OF P53 WT TUMORSApril 2021June 2024Allow3810NoNo
17309098METHODS AND TREATMENTS FOR ERECTILE DYSFUNCTIONApril 2021March 2025Abandon4620NoNo
17287914SMALL MOLECULE VACCINE ADJUVANT FOR ENHANCING OR PROLONGING IMMUNE RESPONSEApril 2021May 2024Allow3620NoNo
17236687MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOFApril 2021August 2024Allow3910NoNo
17285485SOLID DISPERSION OF RIFAMYCIN-NITROIMIDAZOLE COUPLING MOLECULE AND APPLICATION THEREOFApril 2021May 2025Abandon4930NoNo
17284369TRPV4 ACTIVITY INHIBITORApril 2021May 2024Abandon3810NoNo
17282860REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2021August 2024Abandon4001NoNo
17279694USE OF HISTIDINE, GLYCINE AND OTHER AMINO ACIDS FOR PREVENTING INSULIN RESISTANCE AND/OR DIABETESMarch 2021November 2024Abandon4320NoNo
17275177Combination of Palbociclib and Adagrasib for Lung CancerMarch 2021August 2024Allow4140NoNo
17275079SYNERGIC PHARMACEUTICAL COMBINATION OF A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 AND AN ANTHRAQUINONE DERIVATIVEMarch 2021August 2024Abandon4110NoNo
17274136IMIDAZOQUINOLINE COMPOUNDS AND USES THEREOFMarch 2021February 2025Abandon4820NoNo
17192083EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USEMarch 2021May 2024Abandon3810NoNo
17271410SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOFFebruary 2021May 2024Abandon3910NoNo
17271279PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENT AND GASTRIC ACID SECRETION INHIBITORFebruary 2021June 2024Allow4010NoNo
171823876-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyTFebruary 2021May 2024Abandon3910NoNo
17181043ACID ADDITION SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAMEFebruary 2021April 2024Abandon3801NoNo
17265844SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORSFebruary 2021June 2025Abandon5320NoYes
17265678METHOD FOR HYDRATING LYOPHILIZED CYCLOPHOSPHAMIDE COMPOSITION AND PRODUCT THEREOFFebruary 2021June 2025Allow5221YesNo
17264134SYNERGISTICALLY COOPERATIVE COMPOSITIONS USEFUL FOR SOFT TISSUE AUGMENTATION, DRUG DELIVERY AND RELATED FIELDSJanuary 2021November 2024Allow4630NoNo
17262784METHODS OF ACTIVATING MICROGLIAL CELLSJanuary 2021August 2024Abandon4321NoNo
17263126ANTI-BIOFILM COMPOUNDSJanuary 2021September 2024Allow4411NoNo
17153333COMPOSITIONS FOR CYP450 PHENOTYPING USING SALIVA SAMPLESJanuary 2021August 2024Abandon4310NoNo
17148327Purified Detomidine, Process of Preparing and Methods of UseJanuary 2021April 2024Abandon3910NoNo
17258273HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOFJanuary 2021June 2024Allow4120NoNo
17257917PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1January 2021March 2024Allow3810YesNo
17085365Fatty Acid Synthase Inhibitor and Application ThereofOctober 2020December 2023Allow3810NoNo
17006601METHODS AND COMPOSITIONS FOR TREATING VARIOUS DISORDERSAugust 2020April 2025Abandon5681NoNo
16696092Methods Of Treating Follicular LymphomaNovember 2019October 2024Abandon5960NoNo
16441497FORMULATIONS/COMPOSITIONS COMPRISING IBRUTINIBJune 2019September 2024Allow6061YesNo
16468756PARENTERAL LIQUID PREPARATION COMPRISING CARBAMATE COMPOUNDJune 2019April 2024Allow5861YesYes
16323110METHOD FOR THE MANAGEMENT OF DYSMENORRHEA AND MENSTRUAL PAINFebruary 2019March 2025Abandon60101YesNo
15514155PHARMACEUTICAL PREPARATIONMarch 2017March 2024Abandon6071YesNo
15253010STABLE CANNABINOID FORMULATIONSAugust 2016March 2025Abandon6061NoYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAHLIN, HEATHER RAQUEL.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
1
(33.3%)
Not Allowed After Appeal Filing
2
(66.7%)
Filing Benefit Percentile
48.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DAHLIN, HEATHER RAQUEL - Prosecution Strategy Guide

Executive Summary

Examiner DAHLIN, HEATHER RAQUEL works in Art Unit 1629 and has examined 85 patent applications in our dataset. With an allowance rate of 37.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner DAHLIN, HEATHER RAQUEL's allowance rate of 37.6% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DAHLIN, HEATHER RAQUEL receive 1.82 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DAHLIN, HEATHER RAQUEL is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +59.5% benefit to allowance rate for applications examined by DAHLIN, HEATHER RAQUEL. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 12.0% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.